Despite the success of targeted cancer therapies, the duration of clinical response is limited by the inevitable development of acquired drug resistance, as in the case of EGFR-mutated non-small-cell lung cancers (NSCLCs) treated with EGFR inhibitor therapy [1] [2] [3] . Although molecular mechanisms of acquired resistance to EGFR inhibitors have been identified [4] [5] [6] , little is known about how resistant clones evolve during drug therapy. In some cases, clones with clinically validated genetic resistance mechanisms may exist before drug exposure and may be selected for by treatment [7] [8] [9] [10] . Alternatively, it has been hypothesized that drug-tolerant (or 'persister') cells without bona fide resistance mechanisms may survive initial drug treatment by epigenetic adaptations [11] [12] [13] and undergo further evolution over time to acquire validated genetic resistance mechanisms (Supplementary Fig. 1 ). Although this would have immediate implications for new therapeutic strategies to prevent resistance, there has not been any direct evidence that drug-tolerant cells can undergo such an evolution.
To better understand the evolution of acquired resistance, we studied the development of resistance caused by the EGFR T790M gatekeeper mutation, which occurs in 50-60% of individuals with EGFR-mutant NSCLC who have acquired resistance to EGFR inhibitor therapy 4 . By monitoring the development of large numbers of resistant clones in parallel, we were able to identify temporal patterns that reflected the emergence of pre-existing drug-resistant EGFR T790M -positive clones (hereafter referred to as EGFR T790M clones) well as the de novo acquisition of the EGFR T790M mutation within initially EGFR T790M -negative drug-tolerant cells. Moreover, clones that evolved from drug-tolerant cells had epigenetic hallmarks of the drug-tolerant state and a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR T790M . These findings provide evidence that drug-resistant cancer cells bearing the identical clinically relevant genetic resistance mechanism can both pre-exist and evolve from drug-tolerant cells, suggesting that cancer cells that survive initial therapy may serve as an important reservoir from which acquired resistance can emerge in the clinic.
RESULTS

Differential response of PC9-EGFR T790M cells to EGFR inhibition
We previously cultured EGFR-mutated NSCLC PC9 cells in escalating concentrations of the EGFR inhibitor gefitinib until resistant clones (c) Proliferation of parental PC9 (left), PC9-GR2 (middle) and PC9-GR3 (right) cells, as determined by CellTiter-Glo assays at the indicated time points, after treatment with vehicle (Veh) or with 1 µM gefitinib (Gef) or WZ4002 (WZ). Data are mean ± s.e.m. of four independent experiments. The dotted line indicates the relative cell number at the time of drug addition. (d) Change in tumor volume (relative to start of drug treatment), represented as percentage of tumor response, in mice with PC9-GR2-or PC9-GR3-derived subcutaneous xenograft tumors that were treated with WZ4002 (50 mg per kg body weight per day (mg/kg/d)) or left untreated (control) (n = 8 mice per group). Data are mean ± s.e.m. *P < 0.01; by comparing the WZ-treatment arms at the indicated time points by multiple t-tests with Sidak-Bonferroni correction for multiple comparisons. emerged 14 . In two resistant cell lines that acquired the EGFR T790M mutation, there was a marked difference in the time required to develop resistance, with the PC9-GR2 and PC9-GR3 lines developing in 6 and 24 weeks, respectively ( Fig. 1a) . Treatment with the third-generation irreversible EGFR inhibitor WZ4002 (ref. 15 ) suppressed EGFR phosphorylation and downstream mitogen-activated protein kinase (MAPK) kinase (MEK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling, and it induced cell cycle arrest in both resistant cell lines (Supplementary Fig. 2a-c) . However, WZ4002 treatment induced more robust mitochondrial depolarization and subsequent apoptosis in the PC9-GR2 cells than in the PC9-GR3 cells ( Fig. 1b and Supplementary Fig. 2d ). Analysis of the expression of BCL2 family genes, whose products regulate the mitochondrial apoptotic response induced by the MEK and extracellular signal-regulated kinase (ERK) and the PI3K and protein kinase B (AKT) signaling pathways 16 revealed that, as compared to parental and PC9-GR2 cells, PC9-GR3 cells had diminished upregulation of BIM ( Supplementary Fig. 2e,f) , a key mediator of apoptosis in EGFR-mutant NSCLC [17] [18] [19] [20] . Similarly, induction of BIM protein levels after drug treatment was significantly lower (P < 0.05) in PC9-GR3 cells than in PC9-GR2 or parental cells ( Supplementary Fig. 2a,g) . Consistent with the differential levels of apoptosis observed after treatment with WZ4002, a cytotoxic response in PC9-GR2 but not PC9-GR3 cells was induced in vitro after treatment with WZ4002 ( Fig. 1c and Supplementary Fig. 2h ). In vivo, WZ4002 treatment suppressed the growth of subcutaneous PC9-GR3 xenograft tumors, but it did not induce tumor regression to the degree observed for PC9-GR2 tumors (Fig. 1d) , despite comparable inhibition of EGFR and ERK phosphorylation (Supplementary Fig. 3a ).
Early-resistant clones derive from pre-existing EGFR T790Mcontaining cells
The variable time to resistance led us to question whether the PC9-GR2 and PC9-GR3 cells may have developed the EGFR T790M mutation via different mechanisms (i.e., pre-existing mutation versus drug-tolerant evolution (Supplementary Fig. 1) ). To explore this possibility, we cultured over 1,200 small pools (5,000 cells each) of parental PC9 cells in the presence of gefitinib and monitored them for the emergence of resistant clones. After 2 weeks of drug exposure, 5-10% of the wells contained a rapidly growing, resistant colony ( Fig. 2a) , whereas the other wells contained a small number of surviving, drug-tolerant cells similar to those described previously by Settleman and colleagues 11 . Allele-specific quantitative PCR revealed that all 'early-resistant' colonies examined (n = 50) harbored the EGFR T790M mutation (Supplementary Fig. 4a ) and that all of the colonies were sensitive to WZ4002 but not to gefitinib (Fig. 2b) . In contrast, treatment of PC9 pools with WZ4002 treatment for 2 weeks yielded drug-tolerant cells but completely suppressed emergence of the early EGFR T790M colonies (Fig. 2c) . Conversely, treatment of PC9 pools with gefitinib and the insulin-like growth factor (IGF)-1 receptor (IGF-1R) inhibitor AEW541, which was previously shown to abrogate the survival of drug-tolerant PC9 cells 11 , eliminated the drug-tolerant cells without affecting the emergence of early-resistant EGFR T790M clones. These results demonstrate that the early-resistant EGFR T790M clones emerged independently from drug-tolerant cells.
We hypothesized that the early-resistant EGFR T790M clones derived from rare pre-existing EGFR T790M -containing cells that existed in our parental PC9 cell line. Direct detection of genetically distinct rare subpopulations using currently available standard next-generation sequencing (NGS) is limited to allelic frequencies of ~0.1% (ref. 21) , whereas droplet digital PCR (ddPCR) has a sensitivity of 0.01-0.005% (ref. 22 ). In our parental PC9 cell line, we estimated that ~1 out of 25,000-50,000 cells harbor an EGFR T790M allele before treatment (see Online Methods for calculation). Because PC9 cells carry 8-10 copies of EGFR (Supplementary Fig. 4b ) and only one EGFR T790M allele is required to confer resistance ( Supplementary Fig. 4c,d) , direct detection of the pre-existing EGFR T790M clones in our parental PC9 population would necessitate a sensitivity at least an order of magnitude beyond what is routinely achievable.
To overcome these limitations, we used a recently reported highcomplexity DNA barcode library (ClonTracer) designed to track the evolution of pre-existing resistant clones too rare to be detected by NGS or ddPCR 8 . In this system, when a population of barcoded cells is made resistant to drug, enrichment of a shared set of barcodes between multiple replicates indicates selection of pre-existing resistant clones. We transduced ~1 × 10 6 to 2 × 10 6 PC9 cells with lentiviral ClonTracer barcodes, expanded the culture and split it (we refer to this population of cells as replicate group CT-A) into multiple biological replicates of 20 × 10 6 cells each to ensure tenfold representation of barcode complexity ( Supplementary Fig. 5a ). We treated the cells with 300 nM gefitinib and, consistent with our prior experiments, observed rapidly proliferating early-resistant clones at 2-3 weeks. These clones were EGFR T790M positive ( Supplementary Fig. 5b) , and we observed a consistent number of unique barcodes enriched in each replicate ( Fig. 2d and Supplementary Fig. 5c ). Approximately 90% of enriched barcodes in each sample were shared by at least two other replicates, and over 50% of the barcodes were shared by all five replicates ( Fig. 2e and Supplementary Fig. 5d ). Notably, the most highly shared barcodes were also the most highly enriched. We repeated the entire experiment with two additional, independently barcoded PC9 populations (CT-B and CT-C) and found the same results ( Fig. 2e and Supplementary  Fig. 5b-d) . These results confirm that the early-resistant EGFR T790M clones were derived from pre-existing EGFR T790M -mutated cells that were selected for during the gefitinib treatment.
Late-emerging EGFR T790M clones derive from drug-tolerant cells
To determine whether the EGFR T790M allele could also evolve from initially EGFR T790M -negative drug-tolerant cells during drug treatment, we cultured 16 drug-tolerant PC9 cell pools that showed no evidence of early-resistant clones in the continuous presence of gefitinib until they had reached numbers sufficient for genotyping and drugsensitivity testing, which required 12-16 weeks. These pools-which we refer to as 'intermediate-resistant'-remained partially resistant to both gefitinib and WZ4002, and allele-specific PCR for EGFR T790M was negative, indicating non-EGFR T790M -mediated resistance ( Fig. 3a and Supplementary Fig. 6a ). These cells were further cultured in gefitinib until they became fully resistant, and 5 of 16 resistant pools acquired the EGFR T790M mutation and demonstrated increased sensitivity to WZ4002 than to gefitinib ( Fig. 3a and Supplementary Fig. 6b ). To gain a better understanding of the kinetics of evolution of EGFR T790M -mediated resistance in these cells, we examined additional intermediate time points during the development of the original PC9-GR3 resistant line and several of the lateemerging EGFR T790M clones. For the PC9-GR3 line, the EGFR T790M mutation was first detected at 22 weeks, at a fraction of 6% of the total cell population, and within 1 month these cells had overtaken the population as the dominant clone ( Supplementary Figs. 4d and 6c,d) .
For three late-emerging EGFR T790M clones that we examined, a minority EGFR T790M clone was observed at 34, 43 and 47 weeks, respectively, and by 1 month later it had overtaken the population (Supplementary Fig. 6d ). Thus, these results suggest that the EGFR T790M resistance mutation can develop de novo in drug-tolerant cells during the course of prolonged exposure to an EGFR inhibitor.
We subjected resistant cells that remained EGFR T790M negative to a clinical genotyping assay that detects single-nucleotide variants (SNVs) and insertions and deletions (indels) in 39 cancer-related genes 23 . Notably, these EGFR T790M -negative resistant cells had mutations in the oncogenes NRAS, KRAS, BRAF and RET ( Supplementary  Fig. 7a ), although at low allele frequencies, suggesting mixed clonal Supplementary  Fig. 6a ,b). (b) EGFR T790M status of pools of PC9 single-cell-derived subclone A cells after treatment with gefitinib until the cells were fully drug resistant (see also Supplementary Fig. 7b ).
(c) The frequency of PC9 drug-tolerant cell pools developing an EGFR T790M mutation during 16 weeks of drug treatment, mathematically modeled as a function of varying mutational rates (µ) and cell division rates. Frequency values were calculated from the analytical solution of the mathematical model and are depicted as log 10 of the fraction of wells predicted to develop cells with the EGFR T790M mutation. Parameters that yield the experimentally observed frequency of 1.5% are indicated by the solid (mean) and dashed (95% confidence interval) lines. The asterisk (*) denotes parameters used in Figure 3d . The range of the x axis corresponds to a division rate of once every 2 weeks (left) to the rate of PC9 cells in the absence of drug populations. We did not observe amplification of the MET or ERBB2 (also known as HER2) oncogene, and one resistant line had low-level amplification ( Supplementary Fig. 7b ) in KRAS in addition to a KRAS mutation. Although some of these mutations have been previously observed in PC9 cells and in resistant EGFR-mutant NSCLC tumors 24, 25 , the significance of these particular mutations in driving resistance in the clinic is unclear. Of note, the gefitinib-resistant EGFR T790M -negative PC9-GR1 cell line developed in parallel with the PC9-GR2 and PC9-GR3 lines that we previously reported to be sensitive to the combined inhibition of EGFR and MEK 14 developed at a rate nearly identical to that of the drug-tolerant-derived EGFR T790M -positive PC9-GR3 cell line ( Supplementary Fig. 7c ). Taken together, these results suggest that drug-tolerant cells have the potential to develop both EGFR T790M -dependent and EGFR T790Mindependent mechanisms of resistance, which may contribute to the heterogeneity of acquired resistance observed in the clinic 4, 26 .
To further demonstrate that EGFR T790M could evolve during treatment from initially EGFR T790M -negative drug-tolerant cells, we established PC9 subclone lines derived from single cells to eliminate pre-existing EGFR T790M -containing cells. Indeed, in ten independent single-cell subclone lines, no early EGFR T790M colonies emerged after 2 weeks of gefitinib treatment ( Supplementary Fig. 8a) , in contrast to the parental PC9 cells which harbored pre-existing EGFR T790M cells ( Fig. 2a) . We then cultured 14 pools (5,000 cells each) from single-cell subclone A ( Supplementary Fig. 8a ) in gefitinib for up to 40 weeks, until fully resistant cells emerged. Eight pools acquired the EGFR T790M mutation, and six pools remained EGFR T790M nega-tive ( Fig. 3b and Supplementary Fig. 8b) . Similarly, three additional single-cell subclones (B, C and D) were cultured in gefitinib for several months, and all developed late-resistant EGFR T790M clones (data not shown). To provide statistical evidence that these late-emerging EGFR T790M clones did not derive from undetected pre-existing EGFR T790M cells, we spiked single RFP-labeled EGFR T790M PC9 cells into pools of unlabeled subclone A, subclone B, subclone C and subclone D (5,000 cells each) and measured the kinetics of emergence of resistant cells. Over a 10-week time period, all resistant clones were derived from RFP-positive EGFR T790M cells, with the majority emerging within the first 2 weeks (Supplementary Fig. 8c ). From this, we derived a cumulative density function (CDF) describing the probability of detecting the emergence of pre-existing resistant EGFR T790M cells as a function of time ( Supplementary Fig. 8d,e ). Because none of the single cell-derived subclones (A-D) gave rise to early-resistant EGFR T790M clones at 2 weeks ( Supplementary Fig.  8a) , the CDF determined that the probability that the late-resistant EGFR T790M clones that eventually emerged were derived from undetected pre-existing EGFR T790M cells is 0.006 (see legend of Supplementary Fig. 8 for calculation). Taken together, these results confirm that EGFR T790M -acquired resistance can evolve from initially EGFR T790M -negative drug-tolerant cells.
Considering the time scale and cell population sizes of our experiments, we were initially surprised that the EGFR T790M mutation could arise in the slow-growing drug-tolerant cells. Taking into account reasonable estimates of mutation and cell division rates and the experimentally determined growth rates of drug-tolerant cells, we 
Fraction of EGFR T790M -positive pools npg mathematically modeled the de novo acquisition of the EGFR T790M mutation during drug treatment ( Supplementary Fig. 9a,b ; see Online Methods for details) and calculated the fraction of drugtolerant pools that are predicted to acquire the EGFR T790M mutation during 16 weeks of gefitinib treatment for a range of mutation and division rates (Fig. 3c) . This fraction grows linearly with the initial population size and division and mutation rates, and grows exponentially with the growth rate and time (for fractions of <10%). Using a reasonable set of parameters, the mathematical model did predict emergence of the EGFR T790M mutation over a time period corresponding to several months (Fig. 3d) . When we tested this model experimentally, we found that 1.5% of drug-tolerant PC9 pools developed the EGFR T790M mutation over an equivalent time period, in agreement with the modeling results ( Supplementary Fig. 9c ).
To examine whether the EGFR T790M mutation can evolve from drugtolerant cells in other EGFR-mutated NSCLC models, we examined MGH119 cells that were previously derived in our laboratory from a treatment-naive individual with EGFR-mutated NSCLC 14 . MGH119 cells were cultured in gefitinib until they were drug resistant, and two independent EGFR T790M lines (MGH119-GR1 and MGH119-GR2) developed after 5-6 months. To determine whether EGFR T790M cells pre-exist in this model, we treated pools of MGH119 cells with gefitinib for 3 weeks but did not observe any early-resistant colonies (Supplementary Fig. 10a ). In contrast, when we simulated the presence of pre-existing EGFR T790M -containing cells by introducing red fluorescent protein (RFP)-labeled MGH119-GR1 cells in MGH119 parental cell cultures, we detected emerging gefitinib-resistant RFP-positive colonies after 2-3 weeks of drug treatment (Supplementary Fig. 10b ). After 10 weeks of treatment, only RFP-positive resistant clones were observed. These results suggest that the MGH119 cell line does not harbor pre-existing EGFR T790M cells, and that the MGH119-GR1 and MGH119-GR2 resistant cells arose from drug-tolerant cells by acquiring the EGFR T790M mutation during the course of the drug treatment.
Late-resistant EGFR T790M cells have hallmarks of the drug-tolerant state
We next sought to determine whether late-resistant EGFR T790M cells exhibit molecular evidence of evolution from the drug-tolerant state. Using RNA sequencing (RNA-seq) analysis, we compared the transcriptional profiles of drug-tolerant PC9 cells with those of PC9-GR3, PC9-GR2 and parental PC9 cells (Supplementary Fig.  11a ). Principal component analysis (PCA) of mRNA expression at baseline and after treatment with the EGFR inhibitor WZ4002 revealed that the late-resistant EGFR T790M PC9-GR3 cells clustered with drug-tolerant cells and that the early-resistant EGFR T790M PC9-GR2 cells clustered with the parental PC9 cells (Fig. 3e) . Whereas principal component 1 (PC1) primarily differentiated between baseline and drug-treated samples, PC2 segregated PC9-GR3 and drug-tolerant cells from early-resistant PC9-GR2 and parental cells ( Supplementary Fig. 11b ). Gene-set enrichment analysis revealed the upregulation of genes related to epithelialto-mesenchymal transition (EMT) in drug-tolerant and PC9-GR3 cells relative to the parental and PC9-GR2 cells; this pathway has been linked to resistance to EGFR inhibitor therapy in the clinic 4 . These results demonstrate that the late-emerging PC9-GR3 cells share a transcriptional profile most similar to that of drug-tolerant cells. This further supports the model that the late-resistant EGFR T790M cells evolved from drug-tolerant cells ( Fig. 3f) and suggests that molecular features of the drug-tolerant state that impact drug sensitivity may be maintained even after acquisition of the EGFR T790M mutation. 
Late-resistant EGFR T790M cells have reduced apoptosis after EGFR inhibition
By definition, evasion of drug-induced apoptosis is a characteristic feature of drug-tolerant cells (Supplementary Fig. 12 ). Because late-resistant EGFR T790M cells evolved from drug-tolerant cells and continue to share a similar mRNA expression profile as those cells (Fig. 3e) , we reasoned that they might also exhibit reduced apoptotic sensitivity to subsequent EGFR inhibition. Similarly to PC9-GR3 cells (Fig. 1b) , late-resistant EGFR T790M -positive PC9 clones that emerged from drug-tolerant cells had a reduced apoptotic response to WZ4002 treatment as compared to that of early-resistant EGFR T790M clones that were derived from preexisting cells (Fig. 4a) . Moreover, after we induced the expression of EGFR T790M in drug-tolerant cells, the EGFR T790M clones that grew out had reduced apoptotic sensitivity to WZ4002 ( Supplementary  Fig. 13a,b) . MGH119-GR1 and MGH119-GR2 cells-which developed the EGFR T790M mutation late, consistent with evolution from drug-tolerant cells-also exhibited reduced apoptotic response to WZ4002 treatment relative to that of the MGH119 parental cells and the MGH119 cells in which we introduced an EGFR T790Mcontaining allele by using a lentiviral (pTREX) construct ( Fig. 4b and Supplementary Fig. 13c ). These results demonstrate that EGFR T790M cells that evolve from drug-tolerant cells have reduced dependence on EGFR activation for survival as compared to cells with a pre-existing EGFR T790M mutation. This is consistent with the notion that drug-tolerant cells are, by definition, the cells that do not undergo apoptosis after initial EGFR inhibition.
To investigate the clinical implications of the laboratory-derived acquired-resistance models, we examined cell lines derived from EGFR-mutated NSCLC patient tumors at the time of clinical progression due to EGFR T790M -acquired resistance 14 ( Supplementary  Table 1 ). Three cells lines were exquisitely sensitive to WZ4002 treatment (MGH121, MGH164 and MGH141), whereas four had a diminished apoptotic response and increased in vitro survival (MGH134, MGH157, MGH125 and MGH138) ( Fig. 4c,d) . The in vivo sensitivity of MGH141-and MGH134-derived xenograft tumors to WZ4002 treatment mirrored that of the in vitro response-xenografts derived from the MGH134 cell line, which shows diminished apoptosis, failed to undergo tumor regression ( Fig. 4e) , despite suppression of EGFR and ERK signaling ( Supplementary Fig. 3b) .
Notably, the least WZ4002-sensitive cell lines were from patients who had the longest duration of response to first-line EGFR inhibitor therapy before the development of drug resistance (Fig. 4f) , raising the possibility that the EGFR T790M -positive drug-resistant cells with low levels of apoptosis evolved from drug-tolerant cells.
These results suggest that drug-resistant cancers in which the EGFR T790M mutation arises during therapy may have reduced apoptotic sensitivity to third-generation EGFR inhibitors that are currently being evaluated in the clinic [27] [28] [29] . Therefore, we sought to identify therapeutic strategies that could enhance the apoptotic response of these cells to third-generation EGFR inhibitors. Recently, we reported a drug-screening strategy to identify effective drug combinations for cancers with acquired resistance to targeted therapies 14 . Because this screen was focused on overcoming resistance caused by bypass tracks (i.e., compensatory signaling pathways that reestablish activation of key downstream proliferation and survival signals, despite inhibition of the original oncogene), effective drug combinations were identified on the basis of a shift in GI 50 (drug concentration required to achieve 50% growth inhibition) values. However, we noted that the decrease in apoptosis in our models was most clearly reflected by a change in the E max (maximum growth inhibition achieved) values (Supplementary Fig. 14) . We therefore reanalyzed the screening data for three EGFR T790M -positive patient-derived cell lines (MGH134, MGH157 and MGH125) to identify drugs that, in combination with WZ4002 treatment, increased E max values. Additionally, we performed the identical drug screen on PC9-GR3 cells, by using WZ4002 treatment as the anchor. Of the top-scoring compounds for each cell line, the only one common to all four was the dual BCL-xL and BCL-2 inhibitor ABT-263 (also called navitoclax) ( Fig. 5a) . Notably, prior laboratory studies have demonstrated that dual BCL-xL and BCL-2 inhibitors can enhance the apoptotic activity of targeted therapies that induce apoptosis by inducing the expression of BIM 17, 30, 31 , presumably by decreasing the capacity of BCL-xL to neutralize BIM. Treatment with the combination of WZ4002 and navitoclax induced significantly more apoptosis as compared to treatment with WZ4002 alone in both EGFR T790M -positive patient-derived npg cell lines that have low levels of WZ4002-induced apoptosis ( Fig. 5b) and in vitro-generated drug-resistant EGFR T790M cell lines ( Fig. 5c . Combined treatment with WZ4002 and navitoclax also induced regression of MGH134-or PC9-GR3-derived xenograft tumors in mice (Fig. 5d) . Thus, combining navitoclax with third-generation EGFR inhibitors may be an effective strategy for treating EGFR T790Mpositive cancers that have a decreased apoptotic response to EGFR inhibition. Indeed, an upcoming clinical trial will examine the effect of using the combination of AZD9291 and navitoclax to treat EGFRmutated NSCLC with acquired resistance to first-line EGFR inhibitors (ClinicalTrials.gov study NCT02520778).
DISCUSSION
It is now well appreciated that substantial genetic heterogeneity exists between cancer cell clones within a tumor 32, 33 . Pre-existing intratumoral heterogeneity has been shown to influence treatment response and the development of acquired resistance to targeted therapy in some contexts 34 , but there has been little direct clinical evidence to support either emergence of pre-existing resistant clones or de novo evolution as the predominant mechanism of acquired resistance in lung cancer. Several studies have reported the detection of lowfrequency EGFR T790M -positive clones in clinical specimens from patients who had not started treatment yet 9, 35 , although doubts have been raised as to whether the majority of these may be sequencing artifacts related to tissue fixation 10 .
Our results provide a proof of principle that EGFR T790M -positive clones not only emerge from the selection of pre-existing clones but that they also can emerge from initially EGFR T790M -negative drugtolerant cells. Survival of drug-tolerant cancer cells may be facilitated by cell autonomous features such as altered epigenetic states 11, 36 and feedback activation of alternate survival pathways 12 , as well as by external stimuli from the microenvironment 13, 37 . Although these mechanisms may be sufficient to prevent apoptosis and promote survival of drug-tolerant cells, they may not fully recapitulate the optimal oncogenic signaling provided by EGFR. Subsequent acquisition of the EGFR T790M mutation probably provides an additional fitness advantage in the presence of the drug. Thus, drugtolerant cells that are capable of surviving initial drug therapy may provide a reservoir of cells from which genetic mechanisms of acquired resistance can evolve. Consistent with our results, Altschuler and colleagues similarly observed that multiple resistant mechanisms, including that involving EGFR T790M , can develop over time in drug-tolerant cells 38 . Such resistant clones may continue to share molecular features of the drug-tolerant cells (Fig. 3e,f) , leading to a diminished apoptotic response to subsequent therapies. Our finding-that EGFR T790M -positive cell lines derived from tumors of patients who had experienced prolonged responses to firstgeneration EGFR inhibitors had decreased apoptotic responses to third-generation EGFR inhibitors-suggests that tumors in which the EGFR T790M allele arises during the course of therapy may be less responsive to third-generation EGFR inhibitors (such as AZD9291 and CO-1686) 27, 28 in the clinic. However, given the limited number of patient-derived cell lines available for this study, this hypothesis warrants further investigation with additional laboratory models and validation with clinical response data.
We believe that these findings have important clinical implications. These results provide a rationale for the investigation of novel therapeutic strategies to target drug-tolerant cells, before they acquire genetic mechanisms of resistance, to prevent or delay the evolution of acquired resistance. We speculate that the majority of cancer cells that initially survive after therapy probably do not have bona fide drug-resistance mechanisms (such as EGFR T790M -positive tumors) but more closely resemble a drug-tolerant state. Moreover, in light of recent reports that some EGFR T790M -mutant NSCLCs 'lose' the EGFR T790M mutation after developing resistance to AZD9291 or CO-1686 treatment 26, 39 , our studies raise the possibility that EGFR T790M -negative drug-tolerant cells may persist in patients with drug-resistant EGFR T790M -positive tumors and that they undergo further evolution to acquire resistance to subsequent therapies. Because we now know that these drug-tolerant cells can develop genetic mechanisms of drug resistance over time, we believe that it is imperative to develop therapeutic approaches that eliminate this reservoir of drug-tolerant cells that fail to undergo apoptosis. Such treatment strategies will also need to integrate approaches that target the rare pre-existing bona fide drug-resistant clones. We are hopeful that innovative approaches such as these will lead to more complete clinical remissions and improved patient outcomes.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene Expression Omnibus: RNA-seq datasets from parental PC9, drug-tolerant and drug-resistant populations are available through accession number GSE75602.
ONLINE METHODS
Cell lines. The EGFR-mutant NSCLC PC9 cell line (EGFR exon 19, del(E746_A750), EGFR amplified) was obtained from the MGH Center for Molecular Therapeutics. The identity of PC9 parental, GR2 and GR3 cell lines were verified by STR analysis (Bio-synthesis, Inc.) at the time that these studies were performed. EGFR-mutant NSCLC patient-derived cell lines were established in our laboratory from core biopsy or pleural effusion samples as previously described 14, 40 . The MGH1075 stromal fibroblast line was established in our laboratory from a surgical resection specimen of an early-stage primary lung adenocarcinoma. All patients signed informed consent to participate in a Dana-Farber-Harvard Cancer Center Institutional Review Board-approved protocol giving permission for research to be performed on their samples. The HCC827-GR6 line (exon 19 deletion, MET amplified) was previously described 6 . H358 cells were obtained from the Center for Molecular Therapeutics at MGH. PC9-T790M-RFP and MGH119-GR1-RFP cells were generated by infecting the PC9 Early T-1 clone and MGH119-GR1 cells, respectively, with Cignal Lenti RFP (Qiagen) lentivirus followed by puromycin selection. All cell lines were maintained in RPMI (Life Technologies) supplemented with 10% FBS, except for MGH125 and MGH138 cells, which were maintained in ACL4 medium (Life Technologies) with 10% FBS and TCM (3:1 (vol/vol) F-12 nutrient mixture-Dulbecco's Modified Eagle's Medium (Life Technologies), 5% fetal bovine serum, 0.4 µg/ml hydrocortisone, 5 µg/ml insulin, 8.4 ng/ml cholera toxin, 10 ng/ml epidermal growth factor, and 24 µg/ml adenine), respectively. All experiments were performed in RPMI with 10% FBS. All cells were routinely tested and verified to be free of mycoplasma contamination. In vitro generation of gefitinib-resistant cell lines. Gefitinib-resistant PC9-GR2, PC9-GR3 and MGH119-GR1 cells were established by culturing parental cells in escalating concentrations of gefitinib (10 nM-1 µM), as tolerated, as previously described 14 . MGH119-GR2 cells were established by culturing parental cells in full-dose gefitinib (1 µM). Early, drug-tolerant, late PC9 resistant clones were established by culturing in 300 nM gefitinib until resistant, at which point they were maintained in 1 µM gefitinib. During generation of resistance, medium and drug were replaced twice per week.
Generation of PC9 single-cell subclones. PC9 parental cells were seeded into 96-well plates at a density of 0.5 cells/well. After 2 weeks, approximately 25-40% of wells (50-80% of theoretical yield) contained colonies of about 10,000 cells. A minority of wells contained two colonies, which were easily distinguishable. Wells containing only single colonies were expanded an additional 6-10 doublings for use in experiments.
Propidium iodide and annexin V apoptosis assay. Cells were seeded at low density 24 h before addition of drug. 72 h after adding drugs, floating and adherent cells were collected and stained with propidium iodide and Cy5-annexin V (BD Biosciences) and analyzed by flow cytometry. The annexin V-positive apoptotic cell fraction was analyzed using FloJo software (FlowJo, LLC).
CellTiter-Glo proliferation assay.
For dose-response assays, cell lines were seeded into 96-well plates 24 h before addition of drug. Cell proliferation was determined by CellTiter-Glo assay (Promega) 72 h after adding drug, using standard protocols. For time-course experiments, multiple plates were seeded and drugged in identical fashion, and at the indicated time points, the plates were frozen at -80 °C; all plates in an experiment were developed with CellTiter-Glo simultaneously. For early-resistant and drug-tolerant cell experiments, CellTiter-Glo assays were performed at the indicated times on cells in situ.
RealTime-Glo viability assay. Cell viability was assayed in situ once a week starting the day after seeding, using the RealTime-Glo assay (Promega) according to the manufacturer's protocol. Briefly, MT Cell Viability Substrate and NanoLuc Enzyme were diluted 1:500 in medium, and 25 µl was added to each well (1/5 total final volume). Cells were incubated for 1 h at 37 °C and luminescence was measured. For experiments including RFP-labeled cells, RFP fluorescence was measured using excitation at 553 nm and emission at 574 nm. We did not observe any effect of the presence of RFP on RealTime-Glo luminescence or vice versa. Fresh medium containing gefitinib was used to replace the assay reagents immediately after each assay.
Long-term viability assay. Long-term viability assays were completed by plating 1,000-4,000 cells/well in replicate 96-well plates. Cells were treated in quadruplicate 2× per week and fixed at days 0, 3, 7, 14, 21, 28 and 35 with a mixture of formaldehyde (1.0%), PBST (0.04%), and Hoecsht dye (1 µg/ml). Stained nuclei were imaged and then counted using a Molecular Devices ImageXpress Micro high-content imager and MetaXpress software (Molecular Devices).
Cell cycle analysis. Cells were seeded 24 h before experiment to give a confluency of 30-50%. Drugs were added for 24 h and cells were harvested, stained with propidium iodide and analyzed by flow cytometry. Cell cycle subpopulations were calculated using the cell cycle module in FloJo software.
JC-1 mitochondrial depolarization assay. Cells were treated with EGFR inhibitor in the presence of 10 µM QVD-Oph (Sigma) to prevent subsequent apoptosis. 48 h after drug treatment, cells were harvested and stained with JC-1 dye (Life Technologies) according to the manufacturer's recommendations. Treatment with 10 µM CCCP (2-[2-(3-chlorophenyl)hydrazinylyidene]pro panedinitrile; Life Technologies) was used as a positive control. Cells were analyzed by flow cytometry using excitation-emission filters for phycoerythrin (PE) and FITC. Mitochondrial depolarization is indicated by a decrease in the red/green fluorescence intensity ratio.
Quantitative RT-PCR assay for gene expression. Cells were seeded 24 h before give a confluency of 50%. Cells were treated with drugs for 24 h and RNA was extracted using the RNeasy Kit (Qiagen). cDNA was prepared from 500 ng total RNA with the First Strand Synthesis Kit (Invitrogen) using oligo-dT primers. Quantitative PCR was performed using FastStart SYBR Green (Roche) on a Lightcycler 480. mRNA expression relative to actin mRNA levels was calculated using the delta-delta threshold cycle (∆∆C T ) method. Primers used: DUSP6 F 5′-CGACTGGAACGAGAATACGG-3′, R 5′-TTGGAACTTACTGAAGCCACCT-3′; SPRY4 F 5′-CCCCGGCTTC AGGATTTA-3′, R 5′-CTGCAAACCGCTCAATACAG-3′; HER3 F 5′-CTGATCAC CGGCCTCAAT-3′, R 5′-GGAAGACATTGAGCTTCTCTGG-3′; DAPK1 F 5′-CCCTTGTCCCAGTTGAAGAA-3′, R 5′-CCGGTCGAGGAACAT TCA-3′; BIM F 5′-GATCCTTCCAGTGGGTATTTCTCTT-3′, R 5′-ACTGAGA TAGTGGTTGAAGGCCTGG-3′; Actin F 5′-CTGTGCTATCCCTGTACGC CTC-3′, R 5′-CATGATGGAGTTGAAGGTAGTTTCGT-3′; GAPDH F 5′-AACAG CGACACCCATCCTC-3′, R 5′-CATACCAGGAAATGAGCTTGACAA-3′. EGFR T790M quantitative-PCR assay. The EGFR T790M mutation was detected using allele-specific primers (F) 5′-ACCATGCGAAGCCACACTGACG-3′ and (R) 5′-AGCCGAAGGGCATGAGCTGGA-3′ in conjunction with an EGFR exon 20 Taqman probe 5′-ATCACGTAGGCTTCCTGGAG-3′. A commercially available EGFR exon 19-deletion Taqman assay was used as a reference (Hs00000228_mu, Life Technologies). Quantitative PCR was performed on genomic DNA using either FastStart PCR Master or Lightcycler 480 Probes Master kits (Roche) on a Lightcycler 480. For screening assays, ∆Cp(T790M-del19) < 8 was considered positive and ∆Cp > 10 was considered negative (Probes Master), or ∆Cp < 14 was considered positive and ∆Cp > 16 was considered negative (FastStart). EGFR T790M droplet digital PCR analysis. Isolated genomic DNA was amplified using ddPCR Supermix for Probes (Bio-Rad) with EGFR p.T790M (PrimePCR ddPCR Mutation Assay, Bio-Rad) for point-mutation detection. ddPCR was performed according to the manufacturer's protocol, and the results are reported npg as percentage or fractional abundance of mutant DNA alleles to total (mutant plus wild-type) DNA alleles. 8-10 µl of DNA template was added to 10 µl of ddPCR Supermix for Probes (Bio-Rad) and to 2 µl of the primer-probe mixture. Droplets were generated using Auto-DG where the reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad). Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal-cycled with the following conditions: 5 min at 95 °C; 40 cycles of 94 °C for 30 s, 55 °C for 1 min; followed by 98 °C for 10 min (ramp rate 2 °C/s). Droplets were analyzed with the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM (6-carboxyfluorescein) and HEX (hexachlorofluorescein) dye probes. Gating was performed based on positive and negative controls, and mutant populations were identified. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance of the mutant DNA alleles in the wild-type or normal background. Fractional abundance is calculated as follows: F.A. % = ((N Mut / (N Mut + N WT )) × 100), where N Mut is number of mutant events and N WT is number of wild-type (WT) events per reaction. ddPCR analysis of normal control (from cell lines) and no-DNA template controls were always included. Samples with a low number of positive events were repeated at least twice in independent experiments to validate the obtained results.
Clinical genotyping assay. DNA was extracted from late, gefitinib-resistant EGFR T790M -negative PC9 clones using the DNeasy kit (Qiagen). Genotyping was performed using the MGH NGS platform, which utilizes a multiplex polymerase chain reaction (PCR) technology called Anchored Multiplex PCR (AMP) for single-nucleotide variant (SNV) and insertion-deletion (indel) detection in genomic DNA using next-generation sequencing (NGS). Genomic DNA was sheared with the Covaris M220 instrument, followed by end-repair, adenylation, and ligation with an adaptor. A sequencing library targeting hotspots and exons in 39 genes was generated using two hemi-nested PCR reactions. Illumina MiSeq 2 × 151 base paired-end sequencing results were aligned to the hg19 human genome reference using BWA-MEM. MuTect and a laboratory-developed insertion-deletion analysis algorithm were used for SNV and indel variant detection, respectively. This assay has been validated to detect SNV and indel variants at 5% allelic frequency or higher in target regions with sufficient read coverage. Variants are reported with Human Genome Variation Society (HGVS) protein and DNA nomenclature, followed by the referenced Ensembl transcript ID. The gene targets covered by this assay are as follows (exons in parentheses): AKT1 (3), ALK (22, 23, 25) , APC (16) , BRAF (11, 15) , CDH1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16) , CDKN2A (1, 2, 3), CTNNB1 (3), DDR2 (12, 13, 14, 15, 16, 17, 18) , EGFR (7, 15, 18, 19, 20, 21) , ERBB2 (10, 20) , ESR1 (8), FBXW7 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) , FGFR1 (4, 8, 15, 17) , FGFR2 (7, 9, 12, 14) , FGFR3 (7, 8, 9, 14, 16) , FOXL2 (1), GNA11 (5), GNAQ (4, 5), GNAS (6, 7, 8, 9) , HRAS (2, 3), IDH1 (3, 4) , IDH2 (4), KIT (8, 9, 11, 17) , KRAS (2, 3, 4, 5) , MAP2K1 (2, 3), MET (14, 16, 19, 21) , NOTCH (25, 26, 34) , NRAS (2, 3, 4, 5) , PDGFRA (12, 14, 18, 23) , PIK3CA (2, 5, 8, 10, 21) , PIK3R1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) , PTEN (1, 2, 3, 4, 5, 6, 7, 8, 9) , RET (11, 16) , ROS1 (38) , SMAD4 (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) , SMO (9), STK11 (1, 2, 3, 4, 5, 6, 7, 8, 9) , TP53 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) , and VHL (1, 2, 3) .
Gene amplification quantitative PCR assay. Quantitative PCR was performed on genomic DNA using FastStart Sybr Green (Roche) on a Lightcycler 480. Primers for KRAS, MET, a chromosome 12 control and a chromosome 7 control were previously described 41 . EGFR, BRAF and NRAS primers were adapted from Dias-Santagata et al. 42 : EGFR F 5′-CCTCCTTCTGCATGGTATTC-3′, R 5′-GCAGCATGTCAAGATCACAG-3′; BRAF F 5′-TGCTTGCTCTGATAGGAAAATG-3′, R 5′-CTGATGGGAC CCACTCCAT-3′; NRAS F 5′-CAACAGGTTCTTGCTGGTGT-3′, R 5′-GAGAGACAGGATCAGGTCAGC-3′. LINE1 primers: F 5′-AAAGCCGCT CAACTACATGG -3′, R 5′-TGCTTTGAATGCGTCCCAGAG -3′. ∆Cp between gene-control pairs (KRAS-chr. 12, LINE1; MET, EGFR, BRAF-chr. 7, LINE1; HER2, NRAS-LINE1) were calculated and normalized to ∆Cp from a MGH1075 diploid fibroblast control. HCC827-GR6 cells were used as a MET-amplification control 6 and H358 cells were used as KRAS-amplification control.
Generation of tetracycline-inducible EGFR pTREX cell lines.
Plasmids encoding EGFR with and exon 19 deletion (del) and EGFR T790M with an exon 19 del were purchased from Addgene (32062 and 32072, respectively). EGFR sequences were PCR-amplified with the F 5′-CACCATGCGACCCTCCGGGACG-3′ and R 5′-TCATGCTCCAATAAATTCACTG-3′ primers and ligated into the pENTR/D-TOPO vector using the pENTR Directional TOPO Cloning Kits (Invitrogen). The sequence was then introduced into the pTREX vector (kindly provided by Novartis) using Gateway LR Clonase Enzyme (Invitrogen). The pTREX-DEL19 and pTREX-DEL/T790M vectors were subsequently verified by DNA sequencing. Lentivirus was produced using standard procedures 43 . PC9 and MGH119 cells were infected with lentivirus followed by puromycin selection. Cells were cultured in the presence of 10 ng/ml doxycycline to induce expression of the EGFR construct. For infection of PC9 drug-tolerant single cells, cells were infected with a lentiviral titer that yielded a single puromycin-resistant colony in ~50% of wells.
Mouse xenograft studies. All mouse studies were conducted through Institutional Animal Care and Use Committee-approved animal protocols in accordance with institutional guidelines (MGH Subcommittee on Research Animal Care, OLAW Assurance A3596-01). For xenograft studies, cell line suspensions were prepared in 1:10 matrigel and 5 × 10 6 cells were injected subcutaneously into the flanks of female athymic nude (Nu/Nu) mice (6-8 weeks old). Visible tumors developed in approximately 2-4 weeks. Tumors were measured with electronic calipers and the tumor volume was calculated according to the formula Vol = 0.52 × L × W 2 . Mice with established tumors were randomized to drug-treatment groups using covariate-adaptive randomization to minimize differences in baseline tumor volumes: WZ4002 at 50 mg/kg (10% 1-methyl-2pyrolidone, 90% PEG300), ABT-263 at 100 mg/kg (30% PEG400, 60% Phosal 50 PG, 10% ethanol), or combinations thereof. Drug treatments were administered by oral gavage and tumor volumes were measured twice weekly, as described above. For pharmacodynamic studies, mice were sacrificed, and tumors were removed 3 h after drug administration on day 3. Tumors were snap-frozen, and lysates were prepared for western blotting. Investigators performing tumor measurements were not blinded to treatment groups. Sample size (minimum n = 7 per treatment group) was chosen to verify satisfactory interanimal reproducibility.
Estimation of frequency of pre-existing EGFR T790M clones in parental PC9 cells. After 2 weeks of drug exposure, 90 of 1,260 wells were detected to contain resistant EGFR T790M colonies. Based on the above modeling of emergence of pre-existing RFP-labeled EGFR T790M clones, this represents approximately 72% of pre-existing EGFR T790M cells. Thus the theoretical frequency of pre-existing EGFR T790M can be estimated:
(90 colonies /0.7259) 1,260 wells 5,000 cells/well 0.00001968 1 × = ≈ : :50,000
From experiments generating PC9 single-cell clones, the efficiency of single PC9 cells to establish progeny is between 50% and 80%, thus the frequency of EGFR T790M cells in our parental PC9 line is approximately 1:25,000-1:50,000.
ClonTracer barcode library.
Construction of the ClonTracer barcode library and generation of lentiviral particles was previously described 8 . Pools of 10 million PC9 cells were barcoded by lentiviral infection at a multiplicity of infection (MOI) of 0.1-0.2, and infected cells were selected with puromycin. Infected cell populations were expanded in culture for the minimal time period to obtain a sufficient number of cells to set up replicate experiments. 20 million cells (~10× barcode representation) were seeded in multiple replicate plates and treated with vehicle or 300 nM gefitinib (five replicates). Vehicle-treated cells reached confluency within 3 d and the entire pool was pelleted and snap-frozen. Gefitinib-treated plates became confluent from the emergence of early-resistant clones and were harvested after 3 weeks. Cell counts were approximately 20 million cells per replicate plate. Genomic DNA was extracted from the frozen cell populations with a QIAamp DNA Blood Maxi Kit (Qiagen). We used PCR to amplify the barcode sequence for NGS and introduce Illumina adaptors and index sequences 8 . PCR primer sequence information can be found at https://www.addgene.org/pooled-library/clontracer/. The sampling of sufficient template coverage was ensured by parallel PCR reactions.
PCR-amplified products were sequenced on an Illumina HiSeq2500 sequencer in rapid mode using the 50 Cycle TruSeq Rapid v2 SBS Kit, TruSeq Rapid SR v2 Cluster Kit, and HiSeq Rapid SR v2 Flow Cell (Illumina) as previously described 8 . Barcode-composition analysis was carried out as previously described 8 . A barcode was called significant if it was seen at more than 0.01% of the total population in the drug-treated samples (10 times the fraction of the most enriched barcode in the vehicle-treated replicates).
Cumulative density function modeling of emergence of EGFR T790M clones.
Using the cumulative number (N) of RFP + clones detected at each time point, a best-fit model (without being highly sensitive to local noise) was calculated with the Matlab Curve Fitting Tool with fittype exp2, representing a model of the form a × exp (b × x) + c × exp (d × x) . The 95% confidence bounds for the coefficients of equation (1) Mathematical modeling of EGFR T790M evolution from drug-tolerant cells. To model de novo acquisition of the EGFR T790M mutation during drug treatment, we assumed a branching process 44 comprised of N 0 drug tolerant cells that divide at a rate b, die at rate d, and upon birth, mutate at a rate µ. Acquisition of EGFR T790M mutations yields resistant cells that divide at a rate of b r and die at a rate d r . The range of values of the birth and death rates of drug-tolerant cells were based on single-cell parameters reported by Tyson et al. 45 and fit to population growth rates determined by tracking the growth of pools of PC9 drug-tolerant cells during weeks 5-11 of gefitinib treatment (Supplementary Fig. 9a ). The average estimated growth rate determined by fitting the growth curves to an exponential function from the week with the smallest population, which was usually week 6 until week 11, and taking the average was b -d = 0.0015 ± (0.0012)/h. Using the inferred growth rate we back-extrapolated the initial population size of the drug-tolerant cells to be on average N 0 = 150 ± 23. Once a cell acquired the EGFR T790M mutation, the birth and death rate of the resulting EGFR T790M cells were assumed to be similar to those of the PC9 parental cells in the absence of drug (Tyson et al. 45 ). Currently there is no agreement on the average mutation per SNV per cell division, and estimation ranges from 10 −11 up to 10 −7 for non-hypermutated cells 46, 47 . More recent estimates range from 10 −10 to 10 −8 (ref. 48) , with a slight tendency toward lower values. Of note, the EGFR T790M mutation is a change from ACG to ATG-generated by spontaneous deamination of 5-methylcytosine to uracil, which occurs at 18 times greater than the average rate 48 ; furthermore the EGFR gene has a mutation rate that is about twice the average rate 49 across the genome (MutSigCV 50 estimation output). Gene amplification can increase the allelic pool in which a mutation can arise, and PC9 cells have an amplification of the EGFR gene (10 copies per cell; see Supplementary Fig. 4b ) with a single EGFR T790M mutation being sufficient to confer drug resistance. Effectively, the rate of getting an EGFR T790M mutation is about 360 times higher than that of an average SNV. We modeled the process with a Monte Carlo simulation in order to estimate the fraction of drug-tolerant pools predicted to acquire EGFR T790M by 16 weeks after beginning drug treatment. Conversely, we simulated the fraction of drug-tolerant pools predicted to acquire EGFR T790M as a function of time, using fixed parameters. Additionally we derived an analytical approximation to the model
where R represents the fraction of PC9 drug-tolerant pools that acquire an EGFR T790M mutation as a function of time (T). Parameters for drug-tolerant cells: initial population size N 0 = 150, birth rate b = 0.0162, death rate d = 0.015, mutation rate µ = 7 × 10 −10 (estimated to be the average of many estimates by Lynch 49 ). The birth and death rates of EGFR T790M -mutated cells are b r = 0.04 and d r = 0.0015, respectively 45 . In Supplementary Figure 9 , we compare the results of the analytical solution (black line) to the Monte Carlo simulations (red dots) based on 10,000 runs per set of values. The logic behind the solution is to estimate the number of birth events from day 0 to the end of the experiment, which is
and calculate the probability of having at least one EGFR T790M mutation. One should have in mind that the mutation rate in the equation is not the average mutation per SNV per cell division, but rather, it is 360 times higher, as explained above. It is possible that prior models may not have taken this into account, which may explain the differences in the assumed baseline mutational rates between our model and prior models (for example, 10 −8 -10 −7 ) (ref. 44) .
RNA-seq analysis. Total RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA-seq libraries were constructed from polyadenosine (polyA)-selected RNA using NEBNext Ultra Directional RNA library prep kit for Illumina (New England BioLabs) and sequenced on an Illumina HiSeq2500 instrument, resulting in approximately 34 million reads per sample on average. The data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE75602. STAR aligner 51 was used to map sequencing reads to transcripts in the human hg19 reference genome. Read counts for individual transcripts were produced with HTSeq-count 52 , followed by the estimation of expression values and detection of differentially expressed transcripts using EdgeR 53 . Principle component analysis (PCA) was performed on the union of differentially expressed transcripts in all samples. We used the package for gene-set enrichment analysis (GSEA) 54, 55 to analyze the enrichment of functional gene groups among differentially expressed transcripts. Normalized enrichment score (NES) and enrichment plots were calculated based on gene lists ranked by the expression ratio between early (parental PC9 and PC9-GR2) and late (PC9-GR3 and drug tolerant) stages.
Combination drug screen. The combination drug-screening platform has been described previously 14 . Briefly, the panel of screened compounds was comprised of 76 targeted agents directed against a broad range of biologic targets including regulators of growth factor and development signaling pathways, apoptosis, transcription and protein folding, and DNA damage. Cells were treated with vehicle or varying concentrations of drugs to be screened (10,000-fold range), in the absence or presence of 1 µM WZ4002, for 72 h, and cell viability was determined by the CellTiter-Glo assay. Each dose-response curve was normalized to the cell viability of corresponding vehicle-treated cells (with or without WZ4002 treatment). For each dose of a drug in the screen, a ∆E was calculated:
The means of the three highest ∆E values for all of the screened drugs were ranked, and screened drugs that scored 0.20 or higher in at least two of four cell lines were identified.
Data and statistical analysis. Data were analyzed using GraphPad Prism software (GraphPad Software). Unless otherwise specified, data displayed are mean ± s.e.m. Pairwise comparisons between groups (for example, experimental versus control) were made using paired or unpaired Student's t-tests as appropriate.
npg For xenograft tumor measurements, individual time points were compared using multiple t-tests with Sidak-Bonferroni correction for multiple comparisons. For xenograft pharmacodynamic studies, unequal variance between groups was observed in a minority of cases, so a Welch correction was performed for all comparisons. For all other experiments, the variance between comparison groups was verified to be equivalent. Unless otherwise indicated, P < 0.05 was considered to be statistically significant.
